ALLERGAN
LIVE

Serial Number

86983196

Owner

ALLERGAN, INC.

Attorney

Cheryl A. Withycombe

First Use Date

Jun 30, 2017

Filing Date

Jun 12, 2015

Add to watchlist:

No watchlists yet
View on USPTO

ALLERGAN Trademark

Serial Number: 86983196 • Registration: 5443889

ALLERGAN is a trademark filed by ALLERGAN, INC. on June 12, 2015. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). The application is currently registered and active.

Owner Contact Info

ALLERGAN, INC. (1,040 trademarks)

IRVINE, CA 92715

Entity Type: 03

Trademark Details

Filing Date

June 12, 2015

Registration Date

April 10, 2018

First Use Anywhere

June 30, 2017

First Use in Commerce

June 30, 2017

Published for Opposition

March 1, 2016

Goods & Services

House mark used for a line of pharmaceuticals used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma and decongestant formulations, and pharmaceutical preparations to treat and prevent glaucoma; ocular wetting solutions, namely, eye drops, artificial tears and gels for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting sensory organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting the central nervous system; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting urogenital organs; Pharmaceuticals and medicines for the prevention and treatment of conditions affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular disease and blood pressure; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, central nervous system disorders, neurological disorders, neurodegenerative disorders, and depression, neuroprotective agent; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body; medicated cosmetic skin care preparations

House mark used for a line of surgical, medical, dental and veterinary apparatus and instruments, namely, diagnostic test kits principally composed of medical diagnostic meters that measure conditions of the cardio-vascular and immune systems; intra-uterine non-chemical contraceptive devices; medical diagnostic instruments for the analysis of body fluids; medical devices for treating glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for use in facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics and ophthalmic related diseases and disorders

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Aug 20, 2024 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Aug 20, 2024 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Aug 20, 2024 APRE
TEAS SECTION 8 & 15 RECEIVED
Feb 5, 2024 E815
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 10, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 10, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 10, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 10, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 10, 2023 COAR
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Apr 10, 2023 REM1
REGISTERED-PRINCIPAL REGISTER
Apr 10, 2018 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Mar 3, 2018 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Mar 2, 2018 CNPR
TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 9, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Feb 9, 2018 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Feb 8, 2018 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Oct 27, 2017 GNFN
FINAL REFUSAL E-MAILED
Oct 27, 2017 GNFR
SU - FINAL REFUSAL - WRITTEN
Oct 27, 2017 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 25, 2017 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 25, 2017 CRFA
ASSIGNED TO LIE
Oct 24, 2017 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 10, 2017 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 4, 2017 GNRN
NON-FINAL ACTION E-MAILED
Oct 4, 2017 GNRT
SU - NON-FINAL ACTION - WRITTEN
Oct 4, 2017 CNRT
NOTICE OF DESIGN SEARCH CODE E-MAILED
Sep 29, 2017 MDSC
STATEMENT OF USE PROCESSING COMPLETE
Sep 28, 2017 SUPC
DIVISIONAL PROCESSING COMPLETE
Sep 28, 2017 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Sep 28, 2017 AITU
USE AMENDMENT FILED
Sep 20, 2017 IUAF
DIVISIONAL REQUEST RECEIVED
Sep 20, 2017 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Sep 20, 2017 ERTD
TEAS STATEMENT OF USE RECEIVED
Sep 20, 2017 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 28, 2017 EXRA
SOU EXTENSION 2 GRANTED
Mar 24, 2017 EX2G
SOU EXTENSION 2 FILED
Mar 24, 2017 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 24, 2017 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 16, 2016 EXRA
SOU EXTENSION 1 GRANTED
Sep 14, 2016 EX1G
SOU EXTENSION 1 FILED
Sep 14, 2016 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 14, 2016 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 26, 2016 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 1, 2016 NPUB
PUBLISHED FOR OPPOSITION
Mar 1, 2016 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 10, 2016 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 22, 2016 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 22, 2016 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 22, 2016 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 22, 2016 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 22, 2016 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 20, 2016 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 19, 2016 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 19, 2016 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Sep 22, 2015 GPRN
PRIORITY ACTION E-MAILED
Sep 22, 2015 GPRA
PRIORITY ACTION WRITTEN
Sep 22, 2015 CPRA
ASSIGNED TO EXAMINER
Sep 22, 2015 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jun 18, 2015 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 17, 2015 NWOS
NEW APPLICATION ENTERED
Jun 16, 2015 NWAP